HR Execs on the Move

EMD Serono

www.emdserono.com

 
EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany, employing over 1,200 individuals around the country with U.S. headquarters located in Rockland, Massachusetts. The company develops and offers therapies for specialty-care conditions, like multiple sclerosis, infertility and cancer. EMD Serono is committed to transforming lives by developing therapies that patients need and providing industry-leading educational and support programs.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Bruno Galea
 Head of R&D IT Healthcare Operations Profile
John Lee
 Associate Director, Financial Planning & Analysis, Biopharma R&D Profile
Cécile Lloret Jefford
 Director, R&D Strategy Implementation Leader - Strategic Business Development Operations Profile
Jennifer Tose
 Sector HR Business Partner (Director), Healthcare R&D Profile
Rafaela Endert
 Development Chief of Staff - Healthcare R&D Profile

Similar Companies

Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dallas Employment Services

Dallas Employment Services , Inc. is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Teva parenteral Medicines

Teva parenteral Medicines is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoDa Therapeutics

CoDa Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Outlook Therapeutics

Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.